Company intelligence / Profile preview

Trace Biosciences

Beaverton, Oregon, United Statestrace-bio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Trace Biosciences develops targeted imaging agents that highlight nerves in real time during surgery, aiming to reduce or eliminate surgical nerve damage. The company has received Fast-track SBIR funding from ARPA-H and participates in the Cancer Moonshot Precision Surgical Interventions program. It has won several innovation awards but there are no published clinical results yet.

Therapeutic areas: Neurology
Modalities: Imaging agents (nerve-specific fluorescence contrast agents)
Industry: Biotech

Drug pipeline

3 assets

LGW16-03

2 more assets in the full pipeline.

Partnerships

ARPA-H Cancer Moonshot Precision Surgical Interventions program participant

Beyond the preview

Go deeper on Trace Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trace Biosciences.